Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder.
BACKGROUND
This study assessed treatment satisfaction of cystic fibrosis (CF) patients in a routine clinical setting for tobramycin inhalation powder (TIP), the first dry powder-inhaled antibiotic forPseudomonas aeruginosainfection.


METHODS
CF patients aged 6 years or older treated with at least one cycle of TIP completed a web survey on experience with TIP, including the Treatment Satisfaction Questionnaire for Medication (TSQM). Regression analysis determined the factors associated with TSQM global satisfaction.


RESULTS
Eighty patients (mean age ± standard deviation: 24.4±9.4 years; 57.5% female; mean forced expiratory volume in 1 second ± standard deviation: 67.1%±27.3% predicted) completed the survey. The majority expressed satisfaction with TIP's administration time (100%), time to clean (97.1%), portability (97.1%), and ease of use (94.3%). Effectiveness was significantly associated with TSQM global satisfaction (regressionR-squared: 0.54).


CONCLUSIONS
Patient preferences for TIP were based on administration time and ease of use. Global satisfaction was related to greater patient-perceived effectiveness.
Division of Respiratory Diseases, Boston Children's Hospital, Boston, MA.
Jonathan
J
Greenberg
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Jacqueline B
JB
Palmer
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Wing W
WW
Chan
Division of Respiratory Diseases, Boston Children's Hospital, Boston, MA.
Catherine E
CE
Correia
RTI Health Solutions, Manchester, UK.
Diane
D
Whalley
RTI Health Solutions, Manchester, UK.
Paul
P
Shannon
Division of Respiratory Diseases, Boston Children's Hospital, Boston, MA.
Gregory S
GS
Sawicki
cystic fibrosis; dry powder inhalers; patient satisfaction; tobramycin